CALR and cancer: We have demonstrated that the mutant C-terminus of mutant CALR is a cancer neo-antigen as the mutations are immunogenic (6), and both CD4+ and CD8+ T cells specific for peptides derived from the mutant CALR C-terminus recognize and kill autologous CALRmut cells (7, 8).